Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Hematopoietic stem cell transplant (HSCT) is a procedure where healthy hematopoietic stem cells are given to patients with dysfunctional or depleted bone marrow. HSCT therapy is used for both malignant (Acute myeloid leukemia, Myelodysplastic syndromes, Chronic myeloid leukemia, Acute lymphoblastic leukemia, Myeloproliferative disorders, Non-Hodgkin’s lymphoma, Multiple myeloma, Chronic lymphocytic leukemia, Hodgkin’s disease, Juvenile chronic myeloid leukemia)and non-malignant (Aplastic anemia, Paroxysmal nocturnal hemoglobinuria, Fanconi’s anemia, Blackfan-Diamond anemia, Thalassemia major, Sickle cell anemia, Severe combined immunodeficiency, Wiskott-Aldrich syndrome and Inborn errors of metabolism) diseases. In allogeneic hematopoietic stem cell transplantation (HSCT), the stem cells are sourced from a donor different from the recipient. Typically, the donor and recipient share a degree of genetic compatibility known as HLA (human leukocyte antigen) matching, determined by the genes found on chromosome 6. Each individual inherits a set of MHC (major histocompatibility complex) alleles, forming HLA pairs. Crucial HLA loci include HLA-A, HLA-B, HLA-C, HLA-DR, and HLA-DQ. The selection of a donor for allogeneic HSCT considers several factors, including the patient's specific disease, disease stage, and the urgency of finding a suitable donor. In cases where allogeneic HSCT is being contemplated, having a fully HLA-matched sibling as the donor is the preferred choice. This preference is due to the lower risk of graft rejection and graft-versus-host disease (GvHD) when using allogeneic stem cells from a fully HLA-matched sibling. Stem cells can be obtained from three sources: Bone Marrow: This involves a surgical procedure using hollow needles to extract liquid bone marrow from the hip bones. Anticoagulants are added to prevent clumping, and sterile filters remove impurities. Bone marrow can be stored at room temperature, in a refrigerator for a limited time, or cryopreserved for longer storage. Peripheral Blood Progenitor Cells (PBPCs): PBPCs containing HPCs are collected from peripheral blood using an apheresis device. A growth factor is usually administered before collection. Autologous PBPC donors may receive chemotherapy. PBPCs can be stored at room temperature, in refrigerators, or cryopreserved like bone marrow. Umbilical Cord Blood (UCB): UCB, once considered waste, is collected safely after childbirth. Further processing removes red blood cells, which are cryopreserved for future use. UCB can be stored privately or publicly for unrelated recipients. Complications following a bone marrow transplant can be acute or chronic and are influenced by various factors, including age, performance status, stem cell source, and preparative regimen. Acute complications occur within the first 90 days, including myelosuppression, sinusoidal obstruction syndrome, mucositis, graft-versus-host disease, bacterial and viral infections, and fungal infections. Chronic complications encompass chronic GVHD, infections with encapsulated bacteria, and varicella-zoster virus reactivation. The number of allogeneic HCTs performed in the USA increased compared to autologous HCTs. The most common type of allogeneic HCT was from an unrelated donor, followed by transplants from a related donor.

Thelansis’s “Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more